The city of Boston, Massachusetts, currently has 478 active clinical trials seeking participants for Cancer research studies.
Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation
NCT05519293
Recruiting
This is a phase I/IIa, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of H002 when given orally in patients with active EGFR mutation locally advanced or metastatic non-small cell lung cancer (NSCLC). The study will contain two parts: Part A is dose escalation phase (i.e., Phase I) and Part B is dose expansion phase (i.e., Phase IIa).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Non-small Cell Lung Cancer
Register for Updates
ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
NCT03922555
Recruiting
this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive non-enhancing IDH mutant gliomas patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +2 locations
Conditions: Neurological Cancer
Register for Updates
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
NCT03803553
Recruiting
This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer. The names of the potential treatments involved in this study are: * Active surveillance * FOLFIRI treatment * Nivolumab treatment * Encorafenib/Binimetinib/Cetuximab treatment * Trastuzumab + Pertuzumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Metastatic Colon Cancer, Stage III Colon Cancer
Register for Updates
Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
NCT04541654
Recruiting
The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53 variants found in the blood for other reasons (e.g. ACE/CHIP and mosaicism).
Gender:
ALL
Ages:
All
Trial Updated:
03/18/2024
Locations: Boston Children's Hospital, Boston, Massachusetts +2 locations
Conditions: Li-Fraumeni Syndrome, TP53 Gene Mutation, Hereditary Cancer Syndrome, Clonal Hematopoiesis, Mosaicism
Register for Updates
Cryoablation+Ipilimumab+Nivolumab in Melanoma
NCT05779423
Recruiting
The aim of this study is to find out whether the combination of two approved drugs, ipilimumab and nivolumab, in combination with cryoablation are safe and effective for participants who have an unresectable melanoma that is resistant, or is growing, after receiving immunotherapy with a PD-1 inhibitor. The names of the study interventions involved in this study are: * Cryoablation (an interventional radiology procedure that freezes part of a tumor) * Ipilimumab (an immunotherapy) * Nivolumab (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Metastatic Melanoma, Skin Cancer
Register for Updates
Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation
NCT06146920
Recruiting
The goal of this prospective study to investigate the use of circulating tumor DNA (ctDNA) to guide end of therapy decisions in patients with melanoma or non-small-cell lung cancer. The main question it aims to answer is: • Do patients with metastatic melanoma or non-small-cell lung cancer, who have received at least 12 months of immune checkpoint inhibition (monotherapy or in combination) with evidence of disease response/control on imaging and have no evidence of circulating tumor DNA, have... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Melanoma, Non-small Cell Lung Cancer
Register for Updates
Eliminating Barriers to Colorectal Cancer Screening Using Rapid Cycle Testing: A Pilot Study
NCT05524428
Recruiting
The investigators will use a mixed methods study i.e. focus groups involving CHC staff as well as quantitative study which involves analyzing data that is available from the EHR and DRVS population management platform.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Codman Square Health Center, Boston, Massachusetts
Conditions: Colo-rectal Cancer
Register for Updates
Multimodal Machine Learning Characterization of Solid Tumors
NCT04687969
Recruiting
This research study wants to develop advanced imaging methods to more accurately characterize prostate cancer or solid tumor aggressiveness. This observational study involves \[18F\]DCFPyL positron emission tomography and magnetic resonance imaging (PET/MRI)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Adenocarcinoma of Prostate, Radical Prostatectomy, Hepatocellular Carcinoma (HCC), Glioma, Prostate Cancer, Renal Cell Carcinoma (RCC)
Register for Updates
MRI Guided Prostate Biopsy
NCT06302595
Recruiting
This study aims to assess the feasibility of magnetic resonance (MR) guided prostate biopsy using a needle holder frame. This frame is used to help position the needle used for the biopsy. The feasibility in this study is defined as whether the needle holder frame enables accurate tissue sampling from a suspicious region in the prostate found on an MR image. If it does, a biopsy can be carried out with the needle holder frame safely in a clinical routine. The study will be conducted during a rou... Read More
Gender:
MALE
Ages:
30 years and above
Trial Updated:
03/08/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Suspected Prostate Cancer
Register for Updates
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
NCT04634357
Recruiting
Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
03/05/2024
Locations: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts
Conditions: Hepatoblastoma, Hepatocellular Carcinoma (HCC), Liver Neoplasms, Metastatic Liver Cancer, Liver Cancer, HEMNOS
Register for Updates
Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine
NCT03854110
Recruiting
This is a phase 1 first in human, dose escalation trial of GP-2250 administered in combination with gemcitabine in subjects with advanced pancreatic cancer previously treated with 5-fluorouracil-based chemotherapy. Prior radiosensitization with gemcitabine, the use of 5-fluorouracil, FOLFIRINOX or Nab-paclitaxel/gemcitabine in the neoadjuvant setting, and prior pancreaticoduodenectomy (Whipple procedure) is allowed. If prior treatment with gemcitabine was at therapeutic doses, a minimum of 3 mo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Pancreatic Cancer, Adult
Register for Updates
Amivantamab in Adenoid Cystic Carcinoma
NCT05074940
Recruiting
The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/22/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Salivary Gland Cancer
Register for Updates